Conference abstract · 24 Jul 2019
Review articlePublished 27 Aug 2020
Valbenazine for Tardive Dyskinesia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Tardive dyskinesia (TD) remains a clinical concern for any patient who receives an antipsychotic. While the overall risk of developing TD is lower with newer antipsychotics compared to older agents, a significant number of patients who require long-term treatment will develop TD. Recently, valbenazine (brand name Ingrezza) became the first drug to be approved by the FDA specifically for the treatment of TD. In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine. Valbenazine is a modified metabolite of the vesicular monoamine transporter 2 (VMAT-2) inhibitor tetrabenazine, which is approved for the treatment of the hyperkinetic movement disorder, Huntington’s disease. In short-term clinical trials, valbenazine at a dose of 80 mg/day improved TD, with an effect size that is clinically significant (d=0.90). The effect size for the 40-mg/day dose was lower (d=0.52). Compared to tetrabenazine, valbenazine has better clinical characteristics (i.e., once-a-day dosing, better short-term side effect profile). However, only long-term experience in routine clinical populations can delineate valbenazine’s full benefits, optimal dosing, and risks not identified during short-term registration trials.
Subjects
Mental Health and PsychologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2016
Epidemiology of Tardive Dyskinesias in community dwelling schizophrenia patients in rural South India
Conference abstract · 2023
Pyridoxine in treatment of Olanzapine induced Tardive Dyskinesia: A case report
Research article · 29 Sep 2022
Tardive Dyskinesia and the Clinical Concept of Dopamine Super Sensitivity Psychosis in a Patient with Schizoaffective Disorder after Withdrawal of an Atypical Antipsychotic Drug
Review article · 27 Aug 2020
Deuterium Tetrabenazine for Tardive Dyskinesia
More from this journal
The newest in Clinical Schizophrenia & Related Psychoses.
Article · 18 Mar 2026
Antipsychotics vs. ECT with Antipsychotics: A PANSS and SCORS Investigation in Paranoid Schizophrenia
Article · 30 Sep 2025
Successful Treatment of a Treatment Refractory Patient with Clozapine Retrial
Article · 24 Jun 2025
Check the Necessity of Performing A CT Scan of the Brain in Patients with Mild Trauma
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Schizophrenia & Related Psychoses
- SubjectMental Health and Psychology
- BylineArticles whose byline prints “Oliver Freudenreich”
- BylineArticles whose byline prints “Gary Remington”

